REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Phosphorus Containing Other Than Solely As Part Of An Inorganic Ion In An Addition Salt Doai > Nitrogen, Other Than Nitro Or Nitroso, Bonded Indirectly To Phosphorus Nitrogen, Other Than Nitro Or Nitroso, Bonded Indirectly To PhosphorusNitrogen, Other Than Nitro Or Nitroso, Bonded Indirectly To Phosphorus patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021393 - New use of gabab receptor agonists having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts; solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy. ... 01/25/07 - 20070021392 - Divided dose therapies with vascular damaging activity The invention concerns the use of a vascular damaging agent or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal such as a human. In particular the vascular damaging ... 01/25/07 - 20070021391 - Preventive/remedy for urinary disturbance It is intended to provide a preventive/remedy for urinary disturbance containing a compound, which shows an acetylcholine esterase inhibitory activity but substantially has no butyrylcholine esterase inhibitory activity, showing no side effect and being safe and efficacious without inhibiting the urine collection function; a preventive/remedy for dry mouth induced by ... 01/18/07 - 20070015737 - Compounds for inhibiting diseases and preparing cells for transplantation Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid depositions, e.g. in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involved administering to ... 01/11/07 - 20070010494 - Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator wherein A, R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them. ... 01/04/07 - 20070004683 - Mao-b inhibitors useful for treating obesity that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance). ... 12/28/06 - 20060293287 - Storage stable formulation and a process for its preparation The present invention is directed to a storage stable insecticidal composition comprising one or more Chloronicotynyle compound, in an amount ranging from 0.1 to 5% by weight of the composition, one or more compounds falling within the group of Organophosphorus compounds in an amount ranging from 30 to 75% by ... 12/21/06 - 20060287282 - Compositions comprising a sarm ad gnrh agonist or a gnrh antagonist, and methods of use thereof The present invention relates to compositions comprising a selective androgen receptor modulators (SARM) and a gonadotropin releasing hormone (GnRH) agonist or a GnRH antagonist, and their use, inter-alia for treating hormone-associated conditions in males and females, which arise as a result of androgen decline, suppression or abrogation, or in treating, ... 12/07/06 - 20060276438 - Prevention and treatment of influenza with glutamine antagonist agents A method of preventing or treating influenza or an influenza-related symptom in a subject by administering to the subject a glutamine antagonist agent is described. ... 11/30/06 - 20060270636 - Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents. ... 11/16/06 - 20060258628 - Compositions comprising 5-alpha reductase inhibitors, and sarms and methods of use thereof This invention provides a composition comprising a 5-alpha reductase inhibitor and a class of androgen receptor targeting agents (ARTA), which are selective androgen receptor modulators (SARM). The compositions of this invention are useful for, inter-alia, a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated ... 11/02/06 - 20060247214 - Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives A method for treating hair loss in mammals uses compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. Compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives can also be used to lower intraocular pressure and ... 11/02/06 - 20060247213 - Plasma carboxypeptidase b inhibitors Compounds of the following formula (I), for example: (1), wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein. ... 10/19/06 - 20060234986 - Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci This invention relates to TAFI inhibitors and their use to enhance myocardial reperfusion and facilitate percutaneous coronary intervention (PCI) in the treatment of acute ST elevation myocardial infarction (STEMI). ... 10/12/06 - 20060229281 - Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, ... 10/05/06 - 20060223786 - Transdermal pain control method and device Compositions comprising skin-permeable pharmaceutically effective amounts of an opioid agonist; an N-methyl-D-aspartate receptor antagonist and an anti-inflammatory may be incorporated into formulations and devices suitable for transdermal delivery of the active ingredients to alleviate pain. ... 09/21/06 - 20060211659 - Novel compounds of the n-acylamino amide family, compositions comprising them and uses thereof The invention concerns novel compounds of the N-acylamino-amide family, compositions, in particular cosmetic or pharmaceutical, containing them, and their use for treating body or face skin ageing, whether chronobiologic or light-induced, and in particular skin ageing caused by decrease of skin elasticity and/or by collagen degradation in the structure of ... 09/21/06 - 20060211658 - Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator wherein R1, R2, R3, R4, R5, R6, R7, X, Y and n are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them. ... 09/14/06 - 20060205696 - [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain where R1 is H, alkyl or phenylalkyl; R2 is H, alkyl, alkenyl or phenylalkyl; or R1 and R2 taken together as Z are —CH2C—H2—, —CH2C(R6)(R7)CH2— or —CH2C(R8)(R9)—C(R10)(R11)CH2—, where R6, R8 and R10 are, independently, H, alkyl or hydroxyl and R7, R9 and R11 are, independently, H or alkyl; A is ... 09/14/06 - 20060205695 - Novel derivatives of 4,4' dithiobis-(3-aminobutane-1-1-sulfonates) and compositions comprising the same The invention relates to derivatives of 4,4′-dithiobis-(3-aminobutane-1-sulfonates) of formula (1), of use for the treatment and prevention of primary and secondary arterial hypertension. ... 09/07/06 - 20060199788 - Anti-inflammatory phosphonate compounds The invention is related to phosphorus substituted anti-inflammatory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. ... 08/31/06 - 20060194769 - Small molecules that reduce fungal growth The present invention relates to methods for reducing the growth of a fungus with an anti-fungal small molecule. Methods for reducing fungal cell growth in a subject with an anti-fungal small molecule and related compositions are provided. Topical lotion formulations of an anti-fungal small molecule and a topical carrier are ... 08/03/06 - 20060172979 - New use of gabab receptor agonists The present invention relates to the use of GABAB receptor agonists for the treatment as well as the prevention of cough. ... 08/03/06 - 20060172978 - Method of neutralising organoboronates with acids The use of specified compounds for the manufacture of a medicament for therapeutically neutralising an organoboronate drug. The specified compounds are typically hydroxy fatty acids or hydroperoxy fatty acids, for example 9(S)-HODE, 8(S)-HETRE or 8(S)-HEPE, or their salts or prodrugs. The organoboronate drug may be TRI 50c or a salt ... 08/03/06 - 20060172977 - Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage Methods and compositions are provided for preventing, reducing and reversing ischemic neuronal damage related to congenital and acquired ophthalmologic conditions such as macular degeneration, retinitis pigmentosa, optic neuritis, neuroretinitis, Lebers congenital amaurosis, Stargardts disease, Parkinson's disease, diabetic retinopathy, idiopathic senile vision loss, uveitis, edema and ocular surgery. An amount of ... 07/27/06 - 20060166940 - Amino-propanol derivatives wherein R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them. ... 07/20/06 - 20060160777 - New use of gababeta receptor agonists The present invention relates to the use of GABAB receptor agonists for the treatment as well as the prevention of cough. ... 07/20/06 - 20060160776 - Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of ... 07/20/06 - 20060160775 - Combination therapy The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, ... 06/29/06 - 20060142251 - Anti-microbial agents derived from methionine sulfoximine analogues Novel antimicrobial compositions containing analogues of L-methionine-SR-sulfoximine (MSO) that are effective in treating intracellular pathogen infections are provided. Specifically, the compositions provided are MSO analogues having superior antimicrobial activity with significantly less toxicity as compared to MSO. These MSO analogues are suitable for use in treating infection in animals including ... 06/15/06 - 20060128672 - Methods for the administration of amifostine and related compounds The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration. ... 06/15/06 - 20060128671 - Compositions containing a combination of a creatine compound and a second agent The present invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds in combination with neuroprotective agents can be used as therapeutically effective compositions against a variety of diseases ... 05/25/06 - 20060111328 - Carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them when X is S, R3 is not cyclohexyl. The invention further provides pharmaceutical compositions comprising the above compounds and their use in medicine. ... 04/27/06 - 20060089335 - Compositions and methods for enhancing cognitive function and synaptic plasticity The present invention provides compositions and methods for enhancing cognitive function and synaptic plasticity. According to the method, Ca++ influx into excitatory neurons (nerve cells) is decreased by treatment with a number of different agents including divalent cations (e.g., Mg++), GABAB agonists, GABAA agonists, calcium channel blockers, and/or compounds that ... 04/27/06 - 20060089334 - Aminoalkylphosphonates and related compounds as edg receptor agonists The present invention encompasses compounds or Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included. ... 03/23/06 - 20060063743 - Peptide deformylase activated prodrugs This invention provides compounds and methods for using them to inhibit the growth of microorganism that expresses Peptide Deformylase, the compounds having the general formula: ... 03/23/06 - 20060063742 - Method of treatment for or protection against lymphedema A method of reducing the risks of lymphedema, particularly secondary lymphedema associated with surgery or radiotherapy is disclosed. The method of this invention includes administering effective amounts of specific sulfur-containing drug agents according to Formula I herein to a patient at risk of developing lymphedema. ... 03/23/06 - 20060063741 - Compounds useful as pesticides Compounds useful to control pests are provided. ... 03/16/06 - 20060058268 - Compounds and methods for treating diabetic vascular diseases and pharmaceutically acceptable salts thereof for the treatment of diabetic vascular diseases such as diabetic neuropathy, nephropathy, and retinopathy are described, wherein the substituents of the compound are further defined within the application. ... 02/23/06 - 20060040903 - Methods of use related to xerostomia The present invention relates to new uses of thermally stable, crystalline S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by radiation treatment. In particular, the invention provides a method for treating or preventing xerostomia associated with the administration of radiation treatment of head and ... 02/23/06 - 20060040902 - Compunds useful as pesticides Compounds useful to control pests are provided. ... 02/16/06 - 20060035869 - Inhibitors of epoxide hydrolases for the treatment of hypertension wherein X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is ... 02/16/06 - 20060035868 - Functionalized stilbene derivatives as improved vascular targeting agents Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms ... 02/02/06 - 20060025385 - L-dopa amide derivatives and uses thereof L-DOPA amide derivatives, pharmaceutical compositions containing same and their use in the treatment of conditions associated with impaired dopaminergic activity/signaling (e.g., Parkinson disease) are disclosed. ... 01/26/06 - 20060019931 - Treating bone-related disorders with selective androgen receptor modulators This invention provides method of treating, preventing, suppressing, inhibiting, or reducing the risk of developing a bone-related disorder, for example osteoporosis, osteopenia, increased bone resorption, bone fracture, bone frailty and/or loss of bone mineral density (BMD), by administering a therapeutically effective amount of a selective androgen receptor modulator (SARM) and/or ... 12/29/05 - 20050288259 - Composition The present invention relates primarily to an effective long-term simultaneous control of louse infestations and prevention of blowfly strikes on sheep and goats using a specific oil-in-water or water-in-oil topical suspoemulsion formation comprising an insecticidally effective amount of each of the two active ingredients diflubenzuron and dicyclanil and sutiable carriers ... 12/22/05 - 20050282785 - Topical administration of amifostine and related compounds The present invention is directed to methods of treating or protecting mucosal tissue from damage associated with radiation and/or chemotherapeutic treatment of cancers, by the topical application of amifostine and related compounds. These methods avoid the side effects of systemically applied radio/chemo protectants. The invention is also directed to treatment ... 12/01/05 - 20050267077 - Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor The present invention provides methods and compositions for improving cognitive function by administering a GABAB receptor antagonist and an acetylcholinesterase inhibitor. ... 12/01/05 - 20050267076 - Method for improving cognitive function Methods and compositions for improving cognitive function by co-administration of donepezil and a GABAB receptor antagonist are provided. ... 11/24/05 - 20050261253 - Kinase inhibitory phosphonate analogs The invention is related to phosphorus substituted kinase inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. ... 10/13/05 - 20050227948 - Hif hydroxylase inhibitors The invention provides a compound of one of the formulae (A), (B), (C), (D), (E), (F) as herein defined, or a salt thereof, for use in the treatment of a condition associated with increased or decreased HIF levels or activity, or a condition in which an increase or decrease in ... 10/06/05 - 20050222093 - Methods for restoring cognitive function following systemic stress The invention provides methods for treating cognitive decline that is associated with systemic stress. ... 10/06/05 - 20050222092 - Use of s1p receptor agonists in heart diseases The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases. ... 10/06/05 - 20050222091 - Use of tyrosine kinase inhibitors for treating cns disorders The present invention relates to a method for treating CNS disorders, more particularly selected from the group consisting of depression, schizophrenia, anxiety, migraine, memory loss, pain and neurodegenerative diseases, comprising administering a compound capable of depleting mast cells to a human in need of such treatment. Such compounds can be ... 09/29/05 - 20050215531 - Use of edg receptor binding agents in cancer Provided is a method for treating solid tumors, e.g. tumor invasiveness, and particularly inhibiting or controlling deregulated angiogenesis, using a sphingosine-1-phosphate receptor agonist, optionally in combination with a chemotherapeutic agent. The invention also comprises a combination of a sphingosine-1-phosphate receptor agonist with a chemotherapeutic agent. ... 09/29/05 - 20050215530 - Combination therapy for the treatment of cancer The invention relates to a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ... 09/22/05 - 20050209200 - Stable amorphous amifostine compositions and methods for the preparation and use of same The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced ... 09/15/05 - 20050203067 - Pesticidal compositions and methods Certain chemical analogs and related compounds useful in the control nematodes that infest plants or the situs of plants are described. Nematodes that parasitize animals can also be controlled using the methods and compounds of this invention. ... 09/08/05 - 20050197321 - Treatment of sepsis The present invention provides a treatment for sepsis comprising an intravenous solution or pill that contains creatine phosphate and is devoid of carbohydrates. The intravenous solution can be used as a common carrier for antibiotics used to treat the septic condition. Because bacteria cannot utilize creatine phosphate to generate ATP, ... 08/25/05 - 20050187197 - Novel compounds of the n-acylamino amide family, compositions comprising them and uses thereof The invention concerns novel compounds of the N-acylamino-amide family, compositions, in particular cosmetic or pharmaceutical, containing them, and their use for treating body or face skin ageing, whether chronobiologic or light-induced, and in particular skin ageing caused by decrease of skin elasticity and/or by collagen degradation in the structure of ... 08/25/05 - 20050187196 - Treatment of attention disorders The invention provides methods and medicaments for improving attentiveness in humans, including subjects diagnosed with attention disorders. In one aspect, a GABAB receptor antagonist, such as 3-aminopropyl-(n-butyl)-phosphinic acid (ABPA), is used to improve attention. ... 08/18/05 - 20050182031 - Florfenicol prodrug having improved water solubility The present invention discloses phosphate esters of florfenicol (prodrugs) and florfenicol analogs having superior water solubility that are hydrolyzed to florfenicol or the respective florfenicol analog in vivo, upon administration to an animal. ... 08/11/05 - 20050176687 - Use of tyrosine kinase inhibitors for treating autoimmune diseases The present invention relates to a method for treating autoimmune diseases, more particularly selected from the group consisting of multiple sclerosis, ulcerative colitis, Chron's disease, rheumatoid arthritis and polyarthritis, scleroderma, lupus erythematosus, dermatomyositis, pemphigus, polymyositis, vasculitis, as well as graft-versus host diseases, comprising administering a compound capable of depleting mast ... 07/21/05 - 20050159393 - Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents and X is carboxyl (COOH) or carbalkoxy (COOR5), cyano (C≡N), phosphonic acid (PO3H2), phosphonate ester (PO3[R5]2) or 5-tetrazole, and pharmaceutically acceptable salts thereof. Preferably, the compounds are optically pure enantiomers of the R- or S-configuration in which R3=R4=R5=H, R2=CH3 and R1 is a saturated aliphatic chain of one to five ... 07/14/05 - 20050153939 - Combretastatin a-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4. ... 07/07/05 - 20050148549 - Compositions and methods for inhibition of phospholipase a2 mediated inflammation Specific, highly potent 2-oxo-amide based inhibitors of phospholipase A2 (PLA2) activity are provided. A role for PLA2 activity in spinally mediated inflammatory processes is established, and a method for treating hyperalgesia and other inflammatory conditions associated with PLA2 activity is provided. ... 06/30/05 - 20050143351 - Process for preparation of chemically stable, dry-flow, low compact, dust free, soluble granules of phosphoroamidothioates Dry flow, low compact, dust free, soluble granules of phosphoroamidothioates, preferably acephate, are produced by the process of 1) pre-mixing technical grade phosphoroamidothioate with specified adjuvants and other inert ingredients; 2) grinding to produce a ground product having a preferred particle size of 5 microns to 10 microns; 3) post-mixing; ... 06/30/05 - 20050143350 - Combination drug therapy to treat obesity Provided are methods of achieving desirable weight loss in an overweight or obese individual by administering at least one anticholinesterase agent and at least one antidepressant. The invention also provides for pharmaceutical compositions and kits for simultaneous delivery of at least one anticholinesterase agent and at least one antidepressant. ... 06/23/05 - 20050137172 - Haloacetamide and azide substituted compounds and methods of use thereof The present invention relates to a novel class of anti-cancer compounds, which contain a haloacetamide or azide moiety and are, in one embodiment, alkylating agents. These agents, either alone or in a composition, are useful for treating cancer, preventing cancer, delaying the progression of cancer, treating and/or preventing the recurrence ... 06/16/05 - 20050130942 - Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders Compounds useful as antiproliferative agents, including, for example, anticancer agents, are provided according to formula (I); wherein: X, X1, X2, Ra, R1, R2,R3, R4, R5, R6, R7, g, M, y, a, b, d, e, V, W, Z and Q are as defined herein. ... 06/16/05 - 20050130941 - Methods of treating alzheimer's disease Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of hydrazine compounds of formula (I) wherein the variables R1-R9 are defined herein. ... 06/09/05 - 20050124590 - Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells Disclosed are compositions and methods for inhibiting NF-κB mediated cellular proliferation and metastasis. ... ### FreshPatents.com Support |